Celsion Corporation to Hold Third Quarter 2016 Financial Results Conference Call on Thursday, November 10, 2016
November 03 2016 - 8:00AM
Celsion Corporation (NASDAQ:CLSN) announced today that the Company
will host a conference call to discuss financial results for the
quarter and nine-month period ended September 30, 2016 and provide
an update on its development programs for ThermoDox®, its
proprietary heat-activated liposomal encapsulation of doxorubicin
and GEN-1, an IL-12 DNA plasmid vector formulated into a
nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on
Thursday, November 10, 2016. To participate in the call, interested
parties may dial 1-800-533-7619 (Toll-Free/North America) or
1-785-830-1923 (International/Toll) and ask for the Celsion
Corporation 3rd Quarter 2016 Earnings Call (Conference Code:
9409290) to register ten minutes before the call is scheduled to
begin. The call will also be broadcast live over the internet at
www.celsion.com.
The call will be archived for replay on
Thursday, November 10, 2016 and will remain available until
Thursday, November 24, 2016. The replay can be accessed at
1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820
(International/Toll) using Conference Code: 9409290. An audio
replay of the call will also be available on the Company’s website,
www.celsion.com, for 30 days after 2:00 p.m. EDT on Thursday,
November 10, 2016.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in Phase II development for the treatment of
recurrent chest wall breast cancer. The pipeline also
includes GEN-1, a DNA-based immunotherapy for the localized
treatment of ovarian and brain cancers. Celsion has two
platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlas™ and TheraSilence™. For more
information on Celsion, visit our website: www.celsion.com
(CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Sep 2023 to Sep 2024